Complete financial analysis of Tryp Therapeutics Inc. (TRYPF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tryp Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Webuild S.p.A. (IMPJY) Income Statement Analysis – Financial Results
- Chin-Poon Industrial Co., Ltd. (2355.TW) Income Statement Analysis – Financial Results
- Caspin Resources Limited (CPN.AX) Income Statement Analysis – Financial Results
- New Stratus Energy Inc. (NSE.V) Income Statement Analysis – Financial Results
- Fandifi Technology Corp. (FDM.CN) Income Statement Analysis – Financial Results
Tryp Therapeutics Inc. (TRYPF)
About Tryp Therapeutics Inc.
Tryp Therapeutics Inc., a pharmaceutical company, focuses on identifying and developing compounds for diseases with high unmet medical needs. The company's lead development program is (PFN), which is designed to treat neuropsychiatric disorders through the dosing of formulations of synthetic psilocybin. Its PFN program candidates include TRP-8802 and TRP-8803 for fibromyalgia, phantom limb pain, binge eating disorder, complex regional pain syndrome, and hypothalamic obesity. The company has an agreement with the Calvert Labs to design and execute exploratory studies related to psilocybin-for-neuropsychiatric disorders program; and a service agreement with Fluence to provide design and training for the psychotherapeutic portion of Tryp's clinical trial activities. The company was formerly known as Artos Pharma Corp. and changed its name to Tryp Therapeutics Inc. in June 2020. The company was incorporated in 2019 and is based in Kelowna, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.36M | 2.96M | 889.98K | 8.33K |
| General & Administrative | 2.37M | 4.40M | 4.41M | 386.62K |
| Selling & Marketing | 0.00 | 0.00 | 1.98M | 27.67K |
| SG&A | 2.37M | 4.40M | 6.40M | 414.29K |
| Other Expenses | -522.25K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 4.72M | 7.36M | 7.29M | 422.62K |
| Cost & Expenses | 4.72M | 7.36M | 7.29M | 422.62K |
| Interest Income | 1.75K | 3.25K | 10.93K | 0.00 |
| Interest Expense | 522.24K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 167.90K | 228.49K | 236.56K | 206.30K |
| EBITDA | -4.70M | -7.23M | -6.31M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -4.70M | -7.23M | -6.31M | -422.62K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -542.91K | -265.05K | -966.61K | 0.00 |
| Income Before Tax | -5.27M | -7.49M | -8.25M | -422.62K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 538.19K | 123.54K | 959.32K | -458.04 |
| Net Income | -5.27M | -7.49M | -8.25M | -422.62K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.05 | -0.10 | -0.12 | -0.01 |
| EPS Diluted | -0.05 | -0.10 | -0.12 | -0.01 |
| Weighted Avg Shares Out | 96.42M | 78.06M | 66.67M | 38.39M |
| Weighted Avg Shares Out (Dil) | 96.42M | 78.06M | 66.67M | 38.39M |
Tryp Therapeutics to Present at H.C. Wainwright Annual Global Investment Conference
San Diego, California--(Newsfile Corp. - September 1, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it will present...
Tryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of Florida
The training, conducted by Fluence, represents a best-in-class approach for psychotherapy that will accompany the administration of psilocybin for overeating disordersSan Diego, California--(Newsfile Corp. - August 24, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a...
Tryp Therapeutics Appoints Dennis Langer, M.D., J.D. as Senior Advisor
San Diego, California--(Newsfile Corp. - August 18, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the appointment of Dennis Langer,...
Tryp Therapeutics Partners with Calvert Labs to Conduct Exploratory Studies for Proprietary Psilocybin Formulations
Tryp has also entered into an agreement with Gad Consulting Services to collaborate on the preclinical studiesSan Diego, California--(Newsfile Corp. - August 10, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on...
Tryp Therapeutics to Present at Canaccord Genuity Annual Growth Conference
San Diego, California--(Newsfile Corp. - August 3, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it will present...
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Exploring Psilocybin Treatments in Underserved Indications
NEW YORK, July 30, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) announces the availability of a broadcast titled, “Psychedelics — Not Just for Mental Health Anymore.”
Tryp Therapeutics Announces Q3 2021 Financial Results
San Diego, California--(Newsfile Corp. - July 28, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today its...
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Developing Evidence-Based Innovation Where Drugs Are Lacking
NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted...
Tryp Therapeutics Appoints Robin Carhart-Harris, Ph.D. as SAB Chairman and Adds Daniel Clauw, M.D.
San Diego, California--(Newsfile Corp. - July 26, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today the appointment of Robin...
Tryp Therapeutics to Host Q3 Investor Day on July 29, 2021
San Diego, California--(Newsfile Corp. - July 15, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it will host...
Source: https://incomestatements.info
Category: Stock Reports